Avail Primary Care Clinic
Welcome,         Profile    Billing    Logout  
 3 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Johnson, Lisa
PRISM-MEL-301, NCT06112314: IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma

Recruiting
3
680
Europe, US, RoW
Brenetafusp, IMC-F106C, Nivolumab, OPDIVO, Nivolumab + Relatlimab, OPDUALAG
Immunocore Ltd
Advanced Melanoma
10/27
10/27
NCT05023655: Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Recruiting
2
40
US
Tazemetostat, tazverik
Prisma Health-Upstate, Ipsen
Solid Tumor, ARID1A Gene Mutation
01/26
01/27
NCT02938793: Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Recruiting
2
150
US
Durvalumab, MEDI4736, Tremelimumab, CP-675,206
Prisma Health-Upstate, AstraZeneca, MedImmune LLC
Cancer, Rare Disease
12/26
12/28
H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting
1/2
200
Europe, US
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Hookipa Biotech GmbH, Hookipa Biotech
HPV-Related Squamous Cell Carcinoma
06/25
06/26
BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Recruiting
1/2
200
US
BDTX-1535 monotherapy
Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
07/25
06/26
INDP-D101, NCT05651022: Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Recruiting
1/2
120
US
Decoy20, Tislelizumab
Indaptus Therapeutics, Inc, Translational Drug Development
Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer
06/27
09/27
NCT05705505: Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Recruiting
1/2
60
US
Narazaciclib, ON 123300, HX-301, Letrozole 2.5mg, Femara
Onconova Therapeutics, Inc.
Endometrioid Endometrial Cancer
01/26
02/26
MT-5111_001, NCT04029922: Study of MT-5111 in HER2-positive Solid Tumors

Terminated
1
50
US, RoW
MT-5111 (experimental study drug)
Molecular Templates, Inc.
HER2-positive Solid Cancers
02/23
04/23
NCT04739293: Study of ON 123300 in Patients With Advanced Cancer

Recruiting
1
36
US
ON123300, HX 301
Onconova Therapeutics, Inc.
Solid Tumors, Adult
10/24
10/24
RGX-202-001, NCT03597581: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Completed
1
89
US
ompenaclid, RGX-202-01, FOLFIRI, Bevacizumab, FOLFOX regimen
Inspirna, Inc.
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
03/25
03/25
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
NCT06001788: Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
171
Europe, US
Ziftomenib, KO-539, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Xospata, Granulocyte colony-stimulating factor
Kura Oncology, Inc.
AML, AML with Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
08/26
08/27
NCT05923749: A RCT Evaluating the Clinical Benefit of a Silver Dressing in the Treatment of Venous Leg Ulcers

Completed
N/A
180
Europe, US
Biatain Ag, Cutimed Siltec Sorbact
Coloplast A/S
Wound Heal
01/25
01/25
Kober, Lexie Reed
NCT05923749: A RCT Evaluating the Clinical Benefit of a Silver Dressing in the Treatment of Venous Leg Ulcers

Completed
N/A
180
Europe, US
Biatain Ag, Cutimed Siltec Sorbact
Coloplast A/S
Wound Heal
01/25
01/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Johnson, Lisa
PRISM-MEL-301, NCT06112314: IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma

Recruiting
3
680
Europe, US, RoW
Brenetafusp, IMC-F106C, Nivolumab, OPDIVO, Nivolumab + Relatlimab, OPDUALAG
Immunocore Ltd
Advanced Melanoma
10/27
10/27
NCT05023655: Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Recruiting
2
40
US
Tazemetostat, tazverik
Prisma Health-Upstate, Ipsen
Solid Tumor, ARID1A Gene Mutation
01/26
01/27
NCT02938793: Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Recruiting
2
150
US
Durvalumab, MEDI4736, Tremelimumab, CP-675,206
Prisma Health-Upstate, AstraZeneca, MedImmune LLC
Cancer, Rare Disease
12/26
12/28
H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting
1/2
200
Europe, US
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Hookipa Biotech GmbH, Hookipa Biotech
HPV-Related Squamous Cell Carcinoma
06/25
06/26
BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Recruiting
1/2
200
US
BDTX-1535 monotherapy
Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
07/25
06/26
INDP-D101, NCT05651022: Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Recruiting
1/2
120
US
Decoy20, Tislelizumab
Indaptus Therapeutics, Inc, Translational Drug Development
Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer
06/27
09/27
NCT05705505: Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Recruiting
1/2
60
US
Narazaciclib, ON 123300, HX-301, Letrozole 2.5mg, Femara
Onconova Therapeutics, Inc.
Endometrioid Endometrial Cancer
01/26
02/26
MT-5111_001, NCT04029922: Study of MT-5111 in HER2-positive Solid Tumors

Terminated
1
50
US, RoW
MT-5111 (experimental study drug)
Molecular Templates, Inc.
HER2-positive Solid Cancers
02/23
04/23
NCT04739293: Study of ON 123300 in Patients With Advanced Cancer

Recruiting
1
36
US
ON123300, HX 301
Onconova Therapeutics, Inc.
Solid Tumors, Adult
10/24
10/24
RGX-202-001, NCT03597581: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Completed
1
89
US
ompenaclid, RGX-202-01, FOLFIRI, Bevacizumab, FOLFOX regimen
Inspirna, Inc.
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
03/25
03/25
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
NCT06001788: Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
171
Europe, US
Ziftomenib, KO-539, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Xospata, Granulocyte colony-stimulating factor
Kura Oncology, Inc.
AML, AML with Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
08/26
08/27
NCT05923749: A RCT Evaluating the Clinical Benefit of a Silver Dressing in the Treatment of Venous Leg Ulcers

Completed
N/A
180
Europe, US
Biatain Ag, Cutimed Siltec Sorbact
Coloplast A/S
Wound Heal
01/25
01/25
Kober, Lexie Reed
NCT05923749: A RCT Evaluating the Clinical Benefit of a Silver Dressing in the Treatment of Venous Leg Ulcers

Completed
N/A
180
Europe, US
Biatain Ag, Cutimed Siltec Sorbact
Coloplast A/S
Wound Heal
01/25
01/25

Download Options